Clarifying COVID-19 (aka Yes cuz all these sites want to hurt people 🙄)

Two new large-scale reports, one published by Statistics Canada and the other in the Canadian Medical Association Journal, are giving a clearer picture of the long-term impacts of COVID-19 infections on Canadians and the health-care system.

Researchers highlight that it is not clear why type 1 diabetes appears to be more common after coronavirus infection.

People who had COVID-19 are at higher risk for a host of brain injuries a year later compared with people who were never infected by the coronavirus, a finding that could affect millions of Americans, U.S. researchers reported on Thursday.

Individuals with COVID-19 are at an increased risk for an array of neurologic disorders at 12 months, even in those who were not hospitalized during the acute phase of the infection.

September 20, 2022 — Children and adolescents who have either recovered from COVID-19 or have long COVID show persistent lung damage on MRI, according to a

An infectious etiology of Alzheimer’s disease has been postulated for decades. It remains unknown whether SARS-CoV-2 viral infection is associated with increase...

The neurological deficits caused by COVID-19, which were first reported in the early months of 2020, continue to intrigue neurologists and health-care professionals worldwide. As two new studies highlight, these manifestations are frequent and are expected to increase the burden of morbidity and mortality in the acute and chronic phases of COVID-19.

COVID-19 can result in neurological manifestations and animal models could provide insights into the mechanisms. Here, the authors describe neuroinflammation, microhemorrhages and brain hypoxia in SARS-CoV-2 infected non-human primates, including in animals that don’t develop severe respiratory disease.

COVID-19 vaccines show excellent efficacy in clinical trials and effectiveness in real-world data, but some people still become infected with SARS-CoV-2 after vaccination. This study aimed to identify risk factors for post-vaccination SARS-CoV-2 ...

This cross-sectional study examines trends in expected vs observed rates of cancer diagnoses in the US during the first 2 years of the COVID-19 pandemic.

Since the pandemic, there has been a rise in new cancer cases, including rare and aggressive, late-stage cancers — and some physicians and researchers believe that COVID-19 may be behind this increase. Here's what you need to know.

Vaccines safe and immunogenic in most people with cancer.

It has not been shown that COVID-19 vaccines cause or accelerate cancer. Yet opponents of the vaccines say a new review article “has found that COVID-19 mRNA vaccines could aid cancer development.” The review conclusions are mainly based on the misinterpretation of a study on mRNA cancer vaccines in mice.

A new analysis from Oxford Population Health has found that pregnant women that are 30 years old or more, overweight, of mixed ethnicity or have gestational diabetes have a greater risk of

Objectives This study aimed to investigate the impact of pregnancy and pre-existing comorbidities on COVID-19 infections and associated complications of hospitalisation and mortality in women of reproductive age (WRA). The study also compared the risk of severe COVID-19 complications between pregnant women (PW) and non-pregnant women (NPW) with and without pre-existing comorbidities. Special focus was placed on some understudied comorbidities of immunosuppression, chronic renal disease and chronic obstructive pulmonary disease (COPD). Methods The study utilized anonymized patient-related information for a population of 7,342,869 WRA from the Mexican Ministry of Health data repository on COVID-19. Descriptive variables were characterized using frequencies, percentages, means, and standard deviations. Adjusted odds ratios (aORs) were used to assess the associations between risk factors and outcomes of hospitalisation and mortality. The study covered the entire COVID-19 pandemic period from January 30, 2020, to May 5, 2023. Results The findings revealed that PW were not more likely to get COVID-19 infections than NPW. PW with COVID-19 infections were more likely to require hospital admission, intubation treatments, and ICU admission compared to NPW with COVID-19. PW with immunosuppression had an increased odds ratio (aOR) of getting COVID-19 infections compared to NPW (PW: aOR = 1.0396; NPW: aOR = 0.8373). NPW with immunosuppression had higher risk of mortality (all-cause death: aOR = 1.7084; COVID-19-associated death: aOR = 1.4079) and hospitalisation (all-cause hospitalisation: aOR = 4.1328; COVID-19-associated hospitalisation: aOR = 3.0451) than NPW without immunosuppression. Renal disease was identified as a concerning pre-existing condition that increased the risks of COVID-19 associated mortality/hospitalizations and all-cause mortality/hospitalizations for both PW and NPW. NPW with renal disease had much higher odds ratio (aOR) of either COVID-19-associated-hospitalisations (NPW: aOR = 8.639; PW: aOR = 1.7603) or all-cause hospitalisations (NPW: aOR = 8.8594; PW: aOR = 1.786) than PW with renal disease. Conclusions This study provides valuable insights into the impact of pregnancy and pre-existing comorbidities on COVID-19 outcomes in WRA. The findings underscore the importance of considering demographic factors and pre-existing comorbidities in the management of PW with COVID-19. The study also highlights the need for further research to understand the unique impacts of different comorbidities, particularly immunosuppression and renal disease, on COVID-19 outcomes in WRA.

Canadian data suggests people who are pregnant face significantly higher risks of serious COVID-19 requiring hospitalization, ICU admission, or life support — a particular concern because pregnant people tend to have lower rates of vaccination.

Since first being identified in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an etiological agent behind Coronavirus disease 19 (COVID-19), has caused three waves of a global pandemic, with a fourth in progress. ...

On any given day in B.C., the large majority of people in hospital intensive care units are unvaccinated. On Nov. 5, 59 of 64 COVID patients age 59 and younger in I…

Officials said 3.9 per cent of the 400,413 COVID-19 cases between Dec. 14 and June 26 involved partially vaccinated individuals and 0.4 per cent were in those fully immunized.

Studies of a ‘future-proof’ vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals. The

Researchers from the California Institute of Technology say the “mosaic-8” vaccine could protect people from other coronaviruses, including SARS and MERS.

Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic alternatives, China and its sizeable biopharma industry now face a challenging path ahead to catch up to…

China's labs have spent years trying to create an mRNA vaccine - its own shots were less effective.

Having access to an mRNA vaccine will be critical to China’s ongoing COVID response.

Beijing approves the first vaccine of its kind as it looks to jumpstart its flailing economy

TORONTO - Canada's gynecologists say COVID-19 vaccination "remains safe and strongly recommended" during pregnancy and while breastfeeding.

Recent research provides evidence to back the safety and effectiveness of the COVID-19 vaccine for pregnant women.

Pregnant people with COVID-19 are at increased risk of severe illness and death compared with non-pregnant females of reproductive age (aged 15–49 years).1 Additionally, COVID-19 during pregnancy is associated with increased risk for adverse pregnancy outcomes, such as preterm birth and stillbirth.1 When mRNA COVID-19 vaccines first became available in December, 2020, safety data in pregnancy were limited because pregnant people were excluded from pre-authorisation clinical trials.2 Lack of data and safety concerns contributed to initially low uptake among pregnant people, which continues to be lower than uptake among non-pregnant females of reproductive age.

Rare serious complications have been documented after COVID-19 vaccination as clinical research proceeded and new target populations, such as children and ‎pregnant women, were included. In this study, we attempted to review the literature relevant ...